$CVM
CEL SCI CORP Stock $cvm

$cvm Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000165495423015877 Filed on December 21, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.133M	$2.200M	$9.005M
YoY Change	-5.52%	-11.53%	-15.9%
% of Gross Profit
Research & Development	$4.353M	$5.268M	$22.47M
YoY Change	-19.29%	-18.48%	-11.37%
% of Gross Profit
Depreciation & Amortization	$1.005M	$998.7K	$2.114M
YoY Change	1.63%	1.6%	6.93%
% of Gross Profit
Operating Expenses	$6.486M	$7.468M	$31.48M
YoY Change	-15.22%	-16.55%	-12.72%
Operating Profit	-$6.486M		-$31.48M
YoY Change	-15.22%		-12.72%
Interest Expense	-$197.7K	-$181.9K	$675.4K
YoY Change	29.39%	-147.99%	-194.56%
% of Operating Profit
Other Income/Expense, Net	-$25.94K	$18.71K	-$42.81K
YoY Change	-48.3%	-82.54%	-139.96%
Pretax Income	-$6.710M	-$7.631M	-$32.19M
YoY Change	-14.57%	-9.82%	-12.28%
Income Tax
% Of Pretax Income
Net Earnings	-$6.710M	-$7.631M	-$32.19M
YoY Change	-14.57%	-9.82%	-12.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.14	-$0.16	-$0.73
COMMON SHARES
Basic Shares Outstanding	49.98M shares	47.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.258M	$4.150M	$4.150M
YoY Change	-81.92%	-81.7%	-81.7%
Cash & Equivalents	$3.241M	$4.146M	$4.146M
Short-Term Investments	$16.13K	$4.250K	$4.250K
Other Short-Term Assets	$549.8K	$520.4K	$520.4K
YoY Change	2.15%	-31.72%	-31.72%
Inventory	$2.347M	$2.248M	$2.248M
Prepaid Expenses	$549.8K	$520.4K
Receivables
Other Receivables
Total Short-Term Assets	$6.154M	$6.918M	$6.918M
YoY Change	-69.84%	-72.8%	-72.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.644M	$10.19M	$21.02M
YoY Change	-16.29%	-14.31%	-14.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.394M	$2.394M	$2.394M
YoY Change	2188.08%	1356.95%	1356.95%
Total Long-Term Assets	$22.56M	$23.61M	$23.61M
YoY Change	-6.61%	-5.89%	-5.89%
TOTAL ASSETS
Total Short-Term Assets	$6.154M	$6.918M	$6.918M
Total Long-Term Assets	$22.56M	$23.61M	$23.61M
Total Assets	$28.71M	$30.53M	$30.53M
YoY Change	-35.57%	-39.58%	-39.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.144M	$2.010M	$2.010M
YoY Change	-28.47%	24.19%	24.19%
Accrued Expenses	$985.7K	$1.050M	$1.804M
YoY Change	23.08%	24.58%	24.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.827M	$1.772M	$1.772M
YoY Change	14.21%	10.74%	10.74%
Total Short-Term Liabilities	$4.867M	$5.586M	$5.586M
YoY Change	2.64%	19.77%	19.77%
LONG-TERM LIABILITIES
Long-Term Debt	$9.468M	$9.950M	$9.950M
YoY Change	-16.18%	-15.12%	-15.12%
Other Long-Term Liabilities	$125.0K	$125.0K	$1.778M
YoY Change	0.0%	0.0%	-9.99%
Total Long-Term Liabilities	$125.0K	$125.0K	$11.73M
YoY Change	0.0%	0.0%	-14.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.867M	$5.586M	$5.586M
Total Long-Term Liabilities	$125.0K	$125.0K	$11.73M
Total Liabilities	$16.06M	$17.31M	$17.31M
YoY Change	-10.61%	-5.7%	-5.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$493.8M	-$487.1M
YoY Change	6.71%	7.08%
Common Stock	$500.2K	$474.2K
YoY Change	14.39%	9.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.65M	$13.21M	$13.21M
YoY Change
Total Liabilities & Shareholders Equity	$28.71M	$30.53M	$30.53M
YoY Change	-35.57%	-39.58%	-39.58%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$6.710M	-$7.631M	-$32.19M
YoY Change	-14.57%	-9.82%	-12.28%
Depreciation, Depletion And Amortization	$1.005M	$998.7K	$2.114M
YoY Change	1.63%	1.6%	6.93%
Cash From Operating Activities	-$4.888M	-$5.045M	-$22.85M
YoY Change	4.74%	2.67%	25.26%
INVESTING ACTIVITIES
Capital Expenditures	$51.65K	$0.00	$361.9K
YoY Change	-3.6%	-100.0%	-43.27%
Acquisitions
YoY Change
Other Investing Activities	-$13.21K	-$10.37K	-$10.37K
YoY Change			-100.17%
Cash From Investing Activities	-$64.86K	-$10.37K	-$372.3K
YoY Change	21.05%	-35.43%	-106.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.048M	4.066M	$4.694M
YoY Change	6089.41%	-961.85%	-835.31%
NET CHANGE
Cash From Operating Activities	-$4.888M	-5.045M	-$22.85M
Cash From Investing Activities	-$64.86K	-10.37K	-$372.3K
Cash From Financing Activities	$4.048M	4.066M	$4.694M
Net Change In Cash	-$904.3K	-989.3K	-$18.53M
YoY Change	-80.57%	-81.68%	38.38%
FREE CASH FLOW
Cash From Operating Activities	-$4.888M	-$5.045M	-$22.85M
Capital Expenditures	$51.65K	$0.00	$361.9K
Free Cash Flow	-$4.940M	-$5.045M	-$23.21M
YoY Change	4.65%	3.0%	22.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000725363
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43448317	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47422304	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	1-11889
CY2023	dei	Entity Registrant Name EntityRegistrantName	CEL-SCI CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-0916344
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	8229 Boone Blvd.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 802
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Vienna
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22182
CY2023	dei	City Area Code CityAreaCode	703
CY2023	dei	Local Phone Number LocalPhoneNumber	506-9460
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	CVM
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Public Float EntityPublicFloat	97639295	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49980804	shares
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	Potomac, Maryland
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4145735	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22672138	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	520368	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	762063	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2248072	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	2001715	usd
CY2023Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	4245	usd
CY2022Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	6918420	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	25435916	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9131987	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10937797	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1698243	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1884464	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10188126	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11889029	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	197704	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	212201	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2319101	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	0	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	74669	usd
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	164299	usd
CY2023Q3	us-gaap	Assets Assets	30528250	usd
CY2022Q3	us-gaap	Assets Assets	50523706	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2009786	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1618290	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1049581	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	842492	usd
CY2023Q3	cvm	Amounts Due To Employees Current AmountsDueToEmployeesCurrent	557244	usd
CY2022Q3	cvm	Amounts Due To Employees Current AmountsDueToEmployeesCurrent	471488	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1771804	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1560553	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	197431	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	170928	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5585846	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4663751	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	9949565	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	11721368	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1652949	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1850380	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	17313360	usd
CY2022Q3	us-gaap	Liabilities Liabilities	18360499	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47422304	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43448317	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	474223	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	434484	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499832063	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	486625816	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-487091396	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-454897093	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13214890	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	32163207	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30528250	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50523706	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22471496	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25355346	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9004578	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10707447	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	31476074	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	36062793	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-31476074	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-36062793	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	366791	usd
CY2023	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	usd
CY2022	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-30793	usd
CY2023	us-gaap	Interest Expense InterestExpense	675416	usd
CY2022	us-gaap	Interest Expense InterestExpense	1081034	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42813	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	107148	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32194303	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-36700681	usd
CY2023	cvm	Modification Of Warrants ModificationOfWarrants	-171552	usd
CY2022	cvm	Modification Of Warrants ModificationOfWarrants	-929122	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32365855	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37629803	usd
CY2023	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.73
CY2022	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.87
CY2023	cvm	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	44479865	shares
CY2022	cvm	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	43148888	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	56534226	usd
CY2022	cvm	Warrant Exercises Amount WarrantExercisesAmount	171814	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	223043	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	693493	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11389932	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29835	usd
CY2022	cvm	Increase Decrease From Stock Issuance Costs IncreaseDecreaseFromStockIssuanceCosts	178455	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-36700681	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	32163207	usd
CY2023	cvm	Warrant Exercises Amount WarrantExercisesAmount	447291	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	207593	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	565980	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6552497	usd
CY2023	cvm	Incentive Stock Forfeited Amount IncentiveStockForfeitedAmount	-22200	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6308431	usd
CY2023	cvm	Increase Decrease From Stock Issuance Costs IncreaseDecreaseFromStockIssuanceCosts	813606	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32194303	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13214890	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-32194303	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-36700681	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3958334	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3828917	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	15292	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	54469	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	655740	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	762261	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6286231	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11389932	usd
CY2023	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	207593	usd
CY2022	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	223043	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	615	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	366791	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	30793	usd
CY2023	cvm	Gain Loss On Receivables GainLossOnReceivables	0	usd
CY2022	cvm	Gain Loss On Receivables GainLossOnReceivables	-54922	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	151935	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	167651	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-156727	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-159430	usd
CY2023	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-2323346	usd
CY2022	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	1910917	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	257845	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	374890	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	207089	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-16724	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	85756	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	205495	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22848561	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18240951	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	6152000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	361892	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	637892	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10370	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	22741	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-372262	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5491367	usd
CY2023	cvm	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	6552497	usd
CY2022	cvm	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	744913	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	169445	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	447291	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	101225	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29835	usd
CY2023	cvm	Proceeds From Landlord Funding Of Lease Improvements ProceedsFromLandlordFundingOfLeaseImprovements	0	usd
CY2022	cvm	Proceeds From Landlord Funding Of Lease Improvements ProceedsFromLandlordFundingOfLeaseImprovements	786454	usd
CY2023	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	1560455	usd
CY2022	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	1386495	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4694420	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-638426	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-18526403	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13388010	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22672138	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36060148	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4145735	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22672138	usd
CY2023	cvm	Property And Equipment Purchases Included In Current Liabilities PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities	51650	usd
CY2022	cvm	Property And Equipment Purchases Included In Current Liabilities PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities	0	usd
CY2023	cvm	Capitalizable Patent Costs Included In Accrued Expenses And Accounts Payable CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable	13211	usd
CY2022	cvm	Capitalizable Patent Costs Included In Accrued Expenses And Accounts Payable CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable	0	usd
CY2023	cvm	Assets Purchased Under Finance Leases AssetsPurchasedUnderFinanceLeases	0	usd
CY2022	cvm	Assets Purchased Under Finance Leases AssetsPurchasedUnderFinanceLeases	32409	usd
CY2023	cvm	Increase Decrease To Right Of Use Assets And Liabilities IncreaseDecreaseToRightOfUseAssetsAndLiabilities	0	usd
CY2022	cvm	Increase Decrease To Right Of Use Assets And Liabilities IncreaseDecreaseToRightOfUseAssetsAndLiabilities	16268	usd
CY2023	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	1451	usd
CY2022	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	1354	usd
CY2023	cvm	Consulting Fee Paid With Issuance Of Common Stock ConsultingFeePaidWithIssuanceOfCommonStock	565980	usd
CY2022	cvm	Consulting Fee Paid With Issuance Of Common Stock ConsultingFeePaidWithIssuanceOfCommonStock	295143	usd
CY2023	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	77703	usd
CY2022	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	9010	usd
CY2023	cvm	Derivative Liabilities Exercised DerivativeLiabilitiesExercised	0	usd
CY2022	cvm	Derivative Liabilities Exercised DerivativeLiabilitiesExercised	70589	usd
CY2023	cvm	Accrued Consulting Services To Be Paid AccruedConsultingServicesToBePaid	55000	usd
CY2022	cvm	Accrued Consulting Services To Be Paid AccruedConsultingServicesToBePaid	55000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1062564	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1157069	usd
CY2023	cvm	Liquiditydisclosure Textblock LiquiditydisclosureTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2</strong><strong>.</strong> <strong>LIQUIDITY </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) or from the regulators in Canada, the UK or Europe for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of funding, it may have to curtail its operations until such time as it is able to raise the required funding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10188126	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11889029	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2114000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1977000	usd
CY2022Q3	cvm	Deferred Tax Asset Fixed Assets Intangibles And Capitalized Rd DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd	15042000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> – Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company maintains its cash and cash equivalents with high quality financial institutions. At times, these accounts may exceed federally insured limits. The Company has not experienced any losses in such bank accounts. The Company believes it is not exposed to significant credit risk related to cash and cash equivalents. All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2023 and September 30, 2022. </p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> – The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, obsolescence of supplies used for research and development (R&D) and manufacturing, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the derivative liabilities and the lease assets and liabilities to be significant. </p>
CY2023	cvm	Net Loss Gain On Warrant Liabilities NetLossGainOnWarrantLiabilities	0	usd
CY2022	cvm	Net Loss Gain On Warrant Liabilities NetLossGainOnWarrantLiabilities	366791	usd
CY2023	cvm	Deemed Dividend Amount DeemedDividendAmount	294000	usd
CY2023	cvm	Deemed Dividend11 DeemedDividend11	635000	usd
CY2023	cvm	Equity Warrants Exercised EquityWarrantsExercised	217752	shares
CY2023	cvm	Proceeds From Equity Warrants Exercised ProceedsFromEquityWarrantsExercised	447291	usd
CY2023	cvm	Common Stock Issued For Service Shares CommonStockIssuedForServiceShares	249997	shares
CY2022	cvm	Common Stock Issued For Service Shares CommonStockIssuedForServiceShares	156547	shares
CY2023Q3	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	4109070	usd
CY2022Q3	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	4095022	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	99296	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	99296	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	13924724	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	13544394	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18133090	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17738712	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7944964	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5849683	usd
CY2023Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	853445	usd
CY2022Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	893833	usd
CY2023Q3	cvm	Accumulated Amortization AccumulatedAmortization	-655741	usd
CY2022Q3	cvm	Accumulated Amortization AccumulatedAmortization	-681632	usd
CY2023Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	197704	usd
CY2022Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	212201	usd
CY2023	cvm	Patents Weighted Average Amortization Period PatentsWeightedAverageAmortizationPeriod	P8Y
CY2023	cvm	Amortization Of Patent Costs AmortizationOfPatentCosts	38000	usd
CY2022	cvm	Amortization Of Patent Costs AmortizationOfPatentCosts	49000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	32000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	29000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	25000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	22000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	19000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	71000	usd
CY2022Q3	cvm	Total Total	198000	usd
CY2023Q3	cvm	Deferred Tax Assets DeferredTaxAssets	60000000.0	usd
CY2022Q3	cvm	Deferred Tax Assets DeferredTaxAssets	52900000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30829000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25346000	usd
CY2023Q3	cvm	Deferred Tax Asset Fixed Assets Intangibles And Capitalized Rd DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd	15196000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11579000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10442000	usd
CY2023Q3	cvm	Lease Liabilities LeaseLiabilities	3400000	usd
CY2022Q3	cvm	Lease Liabilities LeaseLiabilities	3872000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1221000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1221000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	298000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	307000	usd
CY2023Q3	cvm	Fixed Assets And Intangibles Assets FixedAssetsAndIntangiblesAssets	168000	usd
CY2022Q3	cvm	Fixed Assets And Intangibles Assets FixedAssetsAndIntangiblesAssets	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62691000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56230000	usd
CY2023Q3	cvm	Right Of Use Assets RightOfUseAssets	-2713000	usd
CY2022Q3	cvm	Right Of Use Assets RightOfUseAssets	-3244000	usd
CY2023Q3	cvm	Fixed Assets And Intangibles FixedAssetsAndIntangibles	0	usd
CY2022Q3	cvm	Fixed Assets And Intangibles FixedAssetsAndIntangibles	-44000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2713000	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3288000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	59978000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	52942000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	59978000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52942000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0158	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0167	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0405	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0434	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0162	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0028	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0021	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2185	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2361	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	6286231	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	11389932	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	655740	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	762261	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9918	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0018	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9637	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9926	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0341	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0425	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0150	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0343	pure
CY2023	cvm	Expected Life Of Options Min1 ExpectedLifeOfOptionsMin1	P9Y7M17D
CY2023	cvm	Expected Life Of Options Max ExpectedLifeOfOptionsMax	P9Y7M28D
CY2022	cvm	Expected Life Of Options Min1 ExpectedLifeOfOptionsMin1	P9Y8M1D
CY2022	cvm	Expected Life Of Options Max ExpectedLifeOfOptionsMax	P9Y8M8D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	5509681	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.17
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1547703	shares
CY2022	cvm	Weighted Average Grant Date Fair Value Vested WeightedAverageGrantDateFairValueVested	7.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2040750	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	106331	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	5896397	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.63
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	952256	shares
CY2023	cvm	Weighted Average Grant Date Fair Value Vested WeightedAverageGrantDateFairValueVested	7.30
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2065500	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	213165	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	6796476	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	2.25
CY2022	cvm	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-37629803	usd
CY2023	cvm	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	44479865	shares
CY2023	cvm	Total Compensation TotalCompensation	10000	usd
CY2023	cvm	Participant Compensation ParticipantCompensation	0.06	pure
CY2023	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	97004	shares
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	208000	usd
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	52882	shares
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	223000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	35700000	usd
CY2023	cvm	Net Of Discount NetOfDiscount	11800000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2655000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2740000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2832000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2923000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	3015000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	252000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	14417000	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	2696000	usd
CY2023Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1772000	usd
CY2023Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	9949000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	357000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	366000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	287000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	277000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	285000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1040000	usd
CY2022Q3	cvm	Lessee Operating Lease Liability Payments LesseeOperatingLeaseLiabilityPayments	2612000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	762000	usd
CY2022Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	197000	usd
CY2022Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1653000	usd
CY2023	cvm	Additional Expenses AdditionalExpenses	700000	usd
CY2022	cvm	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	43148888	shares
CY2023	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.73
CY2023	cvm	Proceed From Issuance Or Sale Of Equity ProceedFromIssuanceOrSaleOfEquity	40000	usd
CY2022	cvm	Proceed From Issuance Or Sale Of Equity ProceedFromIssuanceOrSaleOfEquity	10000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	217752	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	25205	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	913234	shares
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.70
CY2023Q2	cvm	Aggregate Net Proceeds From Sale Of Securities AggregateNetProceedsFromSaleOfSecurities	1550000	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2500000	shares
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.00
CY2023Q3	cvm	Aggregate Net Proceeds From Sale Of Securities AggregateNetProceedsFromSaleOfSecurities	5000000.0	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	6000	usd
CY2023	cvm	Weighted Average Risk Free Interest Rate WeightedAverageRiskFreeInterestRate	0.0010	pure
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	437380	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	0	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	70589	usd
CY2023	cvm	Fair Value Measured On Recurring Basis Gain Loss Included Earnings FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings	0	usd
CY2022	cvm	Fair Value Measured On Recurring Basis Gain Loss Included Earnings FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings	-366791	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2023	cvm	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-32365855	usd
CY2022	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.87
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15997278	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14426086	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001654954-23-015877-index-headers.html	Edgar Link	pending
0001654954-23-015877-index.html	Edgar Link	pending
0001654954-23-015877.txt	Edgar Link	pending
0001654954-23-015877-xbrl.zip	Edgar Link	pending
cvm-20230930.xsd	Edgar Link	pending
cvm_10k.htm	Edgar Link	pending
cvm_10kimg10.jpg	Edgar Link	pending
cvm_10kimg11.jpg	Edgar Link	pending
cvm_10kimg14.jpg	Edgar Link	pending
cvm-20230930_pre.xml	Edgar Link	unprocessable
cvm-20230930_cal.xml	Edgar Link	unprocessable
cvm-20230930_lab.xml	Edgar Link	unprocessable
cvm-20230930_def.xml	Edgar Link	unprocessable
cvm_10kimg15.jpg	Edgar Link	pending
cvm_10kimg16.jpg	Edgar Link	pending
cvm_10kimg17.jpg	Edgar Link	pending
cvm_10kimg18.jpg	Edgar Link	pending
cvm_10kimg9.jpg	Edgar Link	pending
cvm_ex231.htm	Edgar Link	pending
cvm_ex31.htm	Edgar Link	pending
cvm_ex32.htm	Edgar Link	pending
cvm_ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
cvm_10k_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVM
CEL SCI CORP Stock $cvm

2023 Q4 Form 10-K Financial Statement

#000165495423015877 Filed on December 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM CEL SCI CORP Stock $cvm

2023 Q4 Form 10-K Financial Statement

#000165495423015877 Filed on December 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM
CEL SCI CORP Stock $cvm